PMID: 8970245Nov 1, 1996Paper

Preclinical evaluation of brimonidine

Survey of Ophthalmology
J Burke, M Schwartz

Abstract

Preclinical studies of brimonidine show that it is a potent alpha 2-adrenoceptor agonist that is 1000-fold more selective for the alpha 2-vs. the alpha 1-adrenoceptor, and is 7-12-fold more alpha 2-selective than clonidine and 23- to 32-fold more alpha 2-selective than apraclonidine (p-aminoclonidine). Brimonidine decreased intraocular pressure (IOP) in various animal models but, unlike apraclonidine, brimonidine was not mydriatic. The site and pharmacology of the IOP response depends on the animal species. In rabbits, the IOP response to brimonidine is mediated by an ocular alpha 2-adrenoceptor while in monkeys, a central nervous system (CNS) 'imidazoline' receptor appears to be involved. Brimonidine decreased IOP by suppressing the rate of aqueous humor flow and enhancing uveoscleral outflow. Topical brimonidine resulted in posterior segment drug levels adequate to activate alpha 2-adrenoceptors, but was not vasoconstrictive in a model designed to assess the vasoactivity of the human retinal microvasculature. Brimonidine protected the rat optic nerve from secondary damage following mechanical injury to the optic nerve and was nontoxic in an array of experiments designed to evaluate ocular and organ toxicity. Taken together, t...Continue Reading

References

May 15, 1990·American Journal of Ophthalmology·E M Van BuskirkW H Fahrenbach
Mar 1, 1989·Archives of Ophthalmology·J S PulidoC F Blodi
Dec 1, 1989·Archives of Ophthalmology·C L SerdahlR A Lewis
Jun 1, 1989·Current Eye Research·J BurkeD Potter
Jan 1, 1985·Journal of Ocular Pharmacology·D L Murray, I H Leopold
Jul 1, 1988·Archives of Ophthalmology·A L Robin
Jul 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·H C InnemeeP A van Zwieten
Dec 1, 1995·Archives of Ophthalmology·C B TorisM E Yablonski
Dec 1, 1994·Current Opinion in Neurology·D R Lynch, T M Dawson

❮ Previous
Next ❯

Citations

Mar 24, 2005·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·S DinslageG K Krieglstein
Sep 3, 2002·Survey of Ophthalmology·Philip F J Hoyng, Yoshi Kitazawa
Nov 1, 1996·Survey of Ophthalmology·J T Wilensky
Apr 12, 2001·Ophthalmology·A R KentD Fellows
Nov 26, 2002·Veterinary Ophthalmology·Kirk N Gelatt, Edward O MacKay
Oct 29, 1998·The New England Journal of Medicine·W L Alward
Jun 28, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Show-Jen HongJim C Fong
Mar 10, 2004·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Eugenia ChuTeh-Ching Chu
Feb 19, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Faruk OztürkSevim Yaman
Jan 19, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Saul MerinItay Chowers
Aug 26, 1998·Australian and New Zealand Journal of Ophthalmology·W E Gillies, A M Brooks
Dec 11, 2002·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Julian Sack
Mar 21, 2013·Investigative Ophthalmology & Visual Science·Yanjun Chen, Randy H Kardon
Mar 19, 2014·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Lisa A EngelArno Hueber
Apr 1, 2011·Drug Delivery and Translational Research·Prakash BhagavSajeev Chandran
Jan 27, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Pooja BansalPradeep Venkatesh
Mar 30, 2006·The Kaohsiung Journal of Medical Sciences·Kwou-Yeung WuHwei-Zu Wang
Apr 29, 2011·Experimental Eye Research·Stella Arthur, Louis B Cantor
Mar 17, 2011·Journal of Clinical Pharmacology·Eulogio BesadaPatrick Hardigan
Jan 4, 2013·Acta Ophthalmologica. Supplement·Anders HeijlUNKNOWN Swedish Ophthalmological Society
Jun 23, 2006·Journal of Clinical Pharmacy and Therapeutics·G P Daubert
Mar 1, 2011·Expert Opinion on Emerging Drugs·Anne J Lee, Ivan Goldberg
Feb 22, 2005·The Journal of Pharmacy and Pharmacology·Jouko SavolainenTomi Järvinen
Mar 5, 2005·Ophthalmology·Theodore KrupinUNKNOWN Low-Pressure Glaucoma Study Group
Apr 7, 2010·Expert Opinion on Drug Safety·Mamun Q RahmanDonald M I Montgomery
Jan 14, 2017·Eye·T Z Khatib, K R Martin
May 10, 2017·Expert Opinion on Pharmacotherapy·Mark S DikopfDeepak P Edward
Mar 15, 2006·Experimental Eye Research·Elaine C JohnsonJohn C Morrison
Jun 29, 2017·Expert Opinion on Drug Safety·Jed Asher Lusthaus, Ivan Goldberg
Feb 21, 2018·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Eugene McLaurinJoseph B Ciolino
Nov 9, 2018·Expert Opinion on Pharmacotherapy·Daniel J OhMark S Dikopf
Mar 16, 2001·Expert Opinion on Pharmacotherapy·A W Talbot, I Russell-Eggitt
Sep 30, 2005·Ophthalmic Research·Josef StoiberJean-Marie Parel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.